102 completed, 17 terminated, 15 recruiting, 11 unknown. 159 Phase 1, 36 Phase 2.
Follow Atopic Dermatitis: new trials by email Literature Review of Atopic Dermatitis trials Research Report on Atopic Dermatitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis baricitinib - Hyper IgE Syndrome From STAT3 Mutation, Job s Syndrome | Phase 1 | Recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | 20 | 2026-11-18 | 2026-11-13 |
| A Phase I Study of GLR2053 Tablets in Chinese Healthy Adult Participants GLR2053 Tablets, Placebo - Atopic Dermatitis | Phase 1 | Not yet recruiting | Gan & Lee Pharmaceuticals. | 124 | 2026-11-05 | 2026-11-06 |
| Phase 1 Study of QX-4533 in Healthy Volunteers and Patients With Moderate-to-Severe Atopic Dermatitis QX4533, QX4533 Placebo - Atopic Dermatitis | Phase 1 | Recruiting | QuantX Biosciences, Inc. | 84 | 2026-09-14 | 2026-10-02 |
| A Study of BYN-001 in Healthy Adults and in Adults With Moderate to Severe Atopic Dermatitis BYN-001, Placebo - Atopic Dermatitis, Healthy Participants | Phase 1 | Recruiting | Bionyra Pharma | 56 | 2026-08-17 | 2026-09-30 |
| A Clinical Study of HRS-8797 in Healthy Participants HRS-8797, Placebo - Atopic Dermatitis | Phase 1 | Not yet recruiting | Chengdu Suncadia Medicine Co., Ltd. | 74 | 2026-07-01 | 2026-07-13 |
| A Dose Escalation Phase 1 Study of HXN5003 in Healthy Participants HXN5003, Placebo - Atopic Dermatitis | Phase 1 | Not yet recruiting | Helixon Biotechnology (Suzhou) Co., Ltd | 28 | 2026-05-27 | 2026-04-24 |
| HL-300 Ointment in Patients With Mild-to-Moderate Atopic Dermatitis HL-300, Placebo - Atopic Dermatitis | Phase 1 / Phase 2 | Recruiting | Hangzhou Highlightll Pharmaceutical Co., Ltd | 156 | 2026-05-26 | 2026-06-23 |
| First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis REGN20423, Placebo - Healthy Volunteer, Atopic Dermatitis | Phase 1 | Recruiting | Regeneron Pharmaceuticals | 160 | 2026-05-22 | 2026-11-06 |
| A Study of IBI3033 in Moderate-to-Severe Atopic Dermatitis IBI3033, Placebo - Atopic Dermatitis | Phase 1 | Not yet recruiting | Innovent Biologics (Suzhou) Co. Ltd. | 16 | 2026-04-30 | 2026-04-24 |
| A Food Effect Study of VC005 Tablets in Healthy Adult Subjects. VC005 Tablets - Atopic Dermatitis | Phase 1 | Completed | Jiangsu vcare pharmaceutical technology co., LTD | 31 | 2026-04-23 | 2026-06-08 |
| A Study of SKB575 (HBM7575) Injection in Healthy Participants and Atopic Dermatitis Participants SKB575 Injection/SKB575 Placebo - Atopic Dermatitis | Phase 1 | Recruiting | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | 90 | 2026-03-31 | 2026-05-08 |
| A Study on the Bioavailability of SHR-1819 Injection Administered Subcutaneously Using Different Injection Devices in Healthy Subjects SHR-1819 Injection - Atopic Dermatitis | Phase 1 | Completed | Guangdong Hengrui Pharmaceutical Co., Ltd | 160 | 2026-03-07 | 2026-08-24 |
| A Study to Compare the Pharmacokinetics, Pharmacodynamic, Immunogenicity, and Safety of CKD-706 With US-Dupixent®, and EU-Dupixent® in Healthy Adult Participants. CKD-706, US-Dupixent, EU-Dupixent - Atopic Dermatitis | Phase 1 | Recruiting | Chong Kun Dang Pharmaceutical | 519 | 2026-02-09 | 2026-01-23 |
| A Clinical Study to Evaluate SM17 in Healthy Participants SM17, SM17 placebo - Atopic Dermatitis, Asthma | Phase 1 | Completed | SinoMab BioScience Ltd | 30 | 2025-10-14 | 2026-04-06 |
| A Study to Learn If the Study Medicine Called PF-08049820 Changes How the Body Processes the Other Study Medicines Called Oral Contraceptives, Midazolam, and Dabigatran in Healthy Adult Female Participants PF-08049820, Midazolam, Dabigatran Etexilate - Atopic Dermatitis | Phase 1 | Completed | Pfizer | 16 | 2025-10-03 | 2026-09-09 |
| A Study to Learn How Different Forms of the Study Medicine Called PF 08049820 Are Taken up Into the Bloodstream in Healthy Adults PF-08049820 MR1, PF-08049820 MR2, PF-08049820 IR - Atopic Dermatitis | Phase 1 | Completed | Pfizer | 12 | 2025-09-05 | 2025-11-17 |
| A Study of BBT001 in Healthy Volunteers (HVs) and in Adult Patients With Moderate to Severe Atopic Dermatitis (AD) BBT001, Placebo - Atopic Dermatitis | Phase 1 | Recruiting | Bambusa Therapeutics | 99 | 2025-08-09 | 2026-07-22 |
| A Study to Evaluate the Safety and Tolerability of Multiple Dose of IBI3002 in Patients With Atopic Dermatitis IBI3002, Placebo - Atopic Dermatitis | Phase 1 | Recruiting | The First Affiliated Hospital of Soochow University | 9 | 2025-07-14 | 2025-08-07 |
| A Study of Two Different Formulations of 611 in Healthy Adult Subjects in China new formulations of 611, existing formulations of 611 - Atopic Dermatitis | Phase 1 | Not yet recruiting | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | 180 | 2025-07-01 | 2025-06-27 |
| An Active Comparator Safety Study Evaluating the Combination of APG777 + APG990 in Moderate-to-Severe Atopic Dermatitis APG777, APG990, Dupilumab - Atopic Dermatitis | Phase 1 | Active not recruiting | Apogee Therapeutics, Inc. | 86 | 2025-06-04 | 2026-10-13 |
Showing 20 of 159. Sign in to see all of them.
Dermatitis, Atopic (159) · Eczema (16) · Dermatitis (8) · Psoriasis (7) · Asthma (5) · Skin Diseases (4) · Hidradenitis Suppurativa (3) · Arthritis, Rheumatoid (2) · Pruritus (2) · Pulmonary Disease, Chronic Obstructive (2) · Rhinitis, Allergic (2) · Urticaria (2) · Alopecia (1) · Autoimmune Diseases (1) · Chronic Urticaria (1)
Congenital, Hereditary, and Neonatal Diseases and Abnormalities (159) · Genetic Diseases, Inborn (159) · Hypersensitivity (159) · Skin and Connective Tissue Diseases (159) · Hypersensitivity, Immediate (158) · Immune System Diseases (158) · Skin Diseases, Eczematous (158) · Skin Diseases, Genetic (158) · Skin Diseases (155) · Dermatitis (151) · Respiratory Tract Diseases (8) · Pathological Conditions, Signs and Symptoms (7) · Respiratory Hypersensitivity (7) · Skin Diseases, Papulosquamous (7) · Bronchial Diseases (5)
dupilumab (4) · 2-(6-(2-(3,5-dichloro-4-pyridyl)acetyl)-2,3-dimethoxyphenoxy)-N-propylacetamide (3) · Midazolam (3) · Caffeine (2) · Clobetasol (2) · Injections, Subcutaneous (2) · Metoprolol (2) · Mometasone Furoate (2) · Ointments (2) · Omalizumab (2) · Omeprazole (2) · Tacrolimus (2) · Warfarin (2) · methyl 4-(((3-(6,7-dimethoxy-2-(methylamino)quinazolin-4-yl)phenyl)amino)carbonyl)benzoate (2) · pimecrolimus (2)
LEO Pharma (14) · National Institute of Allergy and Infectious Diseases (NIAID) (7) · Pfizer (6) · Amgen (4) · Regeneron Pharmaceuticals (4) · Evelo Biosciences, Inc. (3) · Hangzhou Highlightll Pharmaceutical Co., Ltd (3) · Incyte Corporation (3) · Jiangsu vcare pharmaceutical technology co., LTD (3) · AbbVie (2) · Bambusa Therapeutics (2) · Brexogen Inc. (2) · E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd. (2) · Kang Stem Biotech Co., Ltd. (2) · Keymed Biosciences Co.Ltd (2)
United States (61) · China (34) · Germany (15) · Australia (14) · United Kingdom (14) · Canada (7) · Japan (7) · New Zealand (6) · South Korea (6) · Netherlands (5) · Poland (4) · Belgium (2) · France (2) · Puerto Rico (2) · Bangladesh (1)
Duncan McHale, MD, PhD (2) · Henry Milgrom, M.D. (2) · Qianjin Lu (2) · Richard Gallo, M.D., Ph.D. (2) · Alexander Thompson, MBBS (1) · Alexandra F Freeman, M.D. (1) · Aliya Asher, MD (1)
PMID 18645136, PMID 22042247, PMID 23816920, PMID 24331381, PMID 25006719, PMID 25482871, PMID 26581111, PMID 26843086, PMID 27449926, PMID 29498038, PMID 31604104, PMID 32415720, PMID 32428543, PMID 33658996, PMID 35368221, PMID 36344555, PMID 36586583, PMID 37215725, PMID 37668898, PMID 37772436, PMID 37957373, PMID 38846687, PMID 39142926, PMID 39215351, PMID 39404994, PMID 39760983, PMID 40055981, PMID 40221092, PMID 41284735, PMID 41422501, PMID 42143645, PMID 42292382
2014 (4), 2018 (4), 2025 (2), 2017 (1), 2023 (1)